Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma

11 Sept 2024

Abstract excerpt

MGMT promoter methylation is an established prognostic and predictive biomarker in patients with IDH-wildtype glioblastoma.1–3 However, World Health Organization (WHO) central nervous system (CNS) grade 4 IDH-mutant astrocytomas—unlike glioblastoma—uncommonly exhibit monosomy 10 (harboring MGMT), therefore the effect of MGMT promoter methylation on response to alkylating chemotherapy is unclear. Using US registry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39277807
DOI: 10.1093/neuonc/noae157

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytomaPMID 39277807Read ↗

Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapySemantic proximity Read ↗

Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomasSemantic proximity Read ↗

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.Semantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.Semantic proximity Read ↗

MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomasSemantic proximity Read ↗

<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomasSemantic proximity Read ↗

Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification.Semantic proximity Read ↗

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Semantic proximity Read ↗

Unveiling hierarchy and spatial distribution of O6-methylguanine-DNA methyltransferase promoter methylation in World Health Organization grade 2-3 gliomas.Semantic proximity Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.